Early MMR vaccination coverage for infants ages 6–11 months during measles outbreak
Customize your policy alerts
Sign up for Delaware Department of Insurance Policy 167 alerts
Get alerted when Policy 167 changes without checking for updates manually.
Monitor payer policy activity
Directs Delaware-regulated carriers to cover a single early MMR dose for infants 6–11 months during the active measles outbreak, with no cost-sharing, no prior authorization, provider attestation accepted, and operational updates required during the outbreak.
Carriers are required to cover early (accelerated) MMR vaccinations for infants aged 6-11 months during the active measles outbreak.
Providers' clinical determination that an early dose is recommended due to the outbreak is sufficient documentation for coverage.
These expectations apply only during the active outbreak and will sunset when DPH declares the outbreak resolved.
Outbreak-Driven Coverage Rules
Outbreak-driven early MMR dose — coverage criteria
Covered when ALL of the following are met
See DPH outbreak declaration
Carriers should promptly update claims processing and provider communications to ensure coverage without delay.
These expectations apply only while the measles outbreak is active in Delaware and will sunset when DPH declares the outbreak resolved. The Department’s instructions to carriers to cover early (accelerated) MMR doses for infants aged 6–11 months are expressly limited to outbreak response and do not establish routine early‑MMR policy outside of the declared outbreak period.
This document is focused on outbreak‑driven, single early MMR doses for infants aged 6–11 months given in response to confirmed community transmission. It does not attempt to define other clinical situations where an early MMR would be considered not medically necessary or to replace the routine CDC/ACIP schedule; infants who receive an outbreak early dose still require the standard two routine MMR doses after 12 months to complete the series.
Codes and Eligible Age
| No codes listed |
Provider Documentation & Operational Expectations
No prior authorization required
Carriers must reimburse early (accelerated) MMR doses given to infants aged 6–11 months during the active measles outbreak as medically necessary preventive care without requiring prior authorization.
- Applies when dose is administered in response to the outbreak; coverage is statewide during active outbreak.
No administrative barriers or step therapy
Do not impose step therapy or other additional administrative barriers for outbreak-driven early MMR doses; carriers must cover and reimburse these doses without such requirements.
- Expectation applies only during the active measles outbreak and will sunset when DPH declares it resolved.
Provider attestation accepted as sufficient documentation
A provider’s clinical determination that an early MMR dose is recommended because of the ongoing outbreak is sufficient documentation for coverage; carriers should accept provider attestation rather than seeking additional paperwork.
- This standard supports timely access and applies while the outbreak is active.
Denial risk if carrier declines outbreak-driven early MMR
Carriers that decline coverage for early MMR doses administered during the outbreak risk running counter to the Department’s directive; the Bulletin directs carriers not to deny these outbreak-driven early doses.
- Reports indicate some carriers have declined coverage, creating access barriers and reliance on public clinics.
- These expectations are effective immediately and remain until DPH declares the outbreak resolved.
Key Definitions
Clinical and Policy Background
Measles is highly contagious and infants, particularly those under 12 months, are among the most vulnerable to severe complications. Under routine CDC/ACIP guidance the first MMR dose is scheduled at 12–15 months, but during outbreak conditions clinicians may recommend a single early dose for infants aged 6–11 months as part of public health containment efforts.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.